Compare RGS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGS | NRXS |
|---|---|---|
| Founded | 1922 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 78.9M |
| IPO Year | 1994 | 2023 |
| Metric | RGS | NRXS |
|---|---|---|
| Price | $27.75 | $7.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 7.6K | ★ 126.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $224,485,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | 6.83 | ★ 32.89 |
| 52 Week Low | $19.31 | $2.21 |
| 52 Week High | $31.50 | $9.33 |
| Indicator | RGS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.33 |
| Support Level | N/A | $6.51 |
| Resistance Level | N/A | $7.62 |
| Average True Range (ATR) | 0.00 | 0.39 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 0.00 | 73.45 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).